Albendazole metabolites in serum and urine: a first step in developing an indicator of treatment compliance in mass drug administration programs
; Cimino, Rubén Oscar
; Juarez, Marisa del Valle ; Moreno Torrejon, Laura
; Banal, Juan Pablo ; Alvarez, Luis Ignacio
; Krolewiecki, Alejandro Javier
; Judd, Walson ; Lanusse, Carlos Edmundo 
Otros responsables
Fecha
2017
Editorial
Fundación Revista Medicina
Revista
Título del libro
Nombre del evento
LXII Sociedad Argentina de Investigación Clínica; LIII Sociedad Argentina de Investigación Bioquímica y Biología Molecular; LXV Sociedad Argentina de Inmunología, Sociedad Argentina de Andrología; XLVI Sociedad Argentina de Biofísica; XIX Sociedad Argentina de Biología; XLIX Sociedad Argentina de Farmacología Experimental, Reunión Anual de la Sociedad Argentina de Fisiología; Reunión de la Sociedad Argentina de Hematología y XXIX Reunión Anual de la Sociedad Argentina de Protozoología
Fecha del evento
2017-11-13
Institución organizadora
Sociedad Argentina de Investigación Clínica
Sociedad Argentina de Inmunología
Asociación Argentina de Farmacología Experimental
Sociedad Argentina de Biología
Sociedad Argentina de Biofísica
Sociedad Argentina de Protozoología
Sociedad Argentina de Investigación Bioquímica y Biología Molecular
Sociedad Argentina de Andrologia
Sociedad Argentina de Fisiologia
Sociedad Argentina de Inmunología
Asociación Argentina de Farmacología Experimental
Sociedad Argentina de Biología
Sociedad Argentina de Biofísica
Sociedad Argentina de Protozoología
Sociedad Argentina de Investigación Bioquímica y Biología Molecular
Sociedad Argentina de Andrologia
Sociedad Argentina de Fisiologia
ISSN
0025-7680
eISSN
1669-9106
ISBN
Idioma
Inglés
Tipo del evento
Reunión
Clasificación temática
Palabras clave
Resumen
Soil Transmitted Helminth (STH) infections directly impact nutritional status, educational development, individual productivity, and physical and mental development in human populations. Currently, these infections are controlled through mass drug administration (MDA) programs using albendazole (ABZ) or mebendazole. However, not all programs have demonstrated expected impact on prevalence or intensity of infections. These failures may be related to poor programmatic coverage, suboptimal adherence or the exposure of parasites to sub-therapeutic drug concentrations due to poor drug dissolution, insufficient gastrointestinal absorption and/or systemic availability of the active ingredient. The aims of the present work were to characterize the serum disposition kinetics and pattern of urinary excretion of ABZ and its main metabolites, ABZ sulphoxide (ABZSO) and ABZ sulphone (ABZSO2 ) in human volunteers, and to determine the optimal time point where ABZ and/or its metabolites can be measured in urine as an indirect assessment of an individual’s adherence to treatment. Venous blood and urine samples were collected from eight (8) volunteers between 2 and 72 h for HPLC analysis of ABZ/metabolites, following administration of a single postprandial oral dose of ABZ (400 mg). The ABZSO metabolite was the main analyte recovered either in serum and urine samples from ABZ-treated human. ABZSO serum concentrations reached its peak concentration (Cmax= 1.20 ± 0.44 μg/mL) at 4.75 h post-treatment. In urine, ABZSO Cmax value was 3.24 ± 1.51 μg/mL, reached at 6.50 h post ABZ administration. The urinary AUC value resulted higher (2.3 fold) compared to that measured in serum. The overall, PK-based information reported here demonstrates that the measurement of ABZSO concentrations both, in serum and urine, could be useful to confirm compliance to ABZ treatment and an objective measurement of program coverage.
Colecciones
Aprobación
Revisión
Complementado por
Referenciado por
Licencia Creative Commons
Excepto donde se indique lo contrario, la licencia de este ítem se describe como by-nc-sa
